<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Two phase I studies of the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan combination were performed in advanced <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> patients to characterize the safety and pharmacokinetics of the regimen </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients with a performance status (PS) of &lt; or = 2 and <z:mpath ids='MPATH_458'>normal</z:mpath> hematologic, hepatic, and renal functions received <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (2-hour intravenous infusion) followed 1 hour later by irinotecan administered over a 30-minute period, every 3 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Dose levels that were explored ranged from 85 to 110 mg/m(2) for <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and 150 to 250 mg/m(2) for irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma pharmacokinetics of total and ultrafiltrable <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>, irinotecan, SN-38, and its <z:chebi fb="0" ids="24302">glucuronide</z:chebi>, SN-38G, were determined </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Thirty-nine patients with <z:hpo ids='HP_0002672'>gastrointestinal carcinomas</z:hpo> (24 with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>], four with <z:mp ids='MP_0009153'>pancreas cancer</z:mp>, four with <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, three with <z:e sem="disease" ids="C0019204" disease_type="Neoplastic Process" abbrv="">hepatocarcinoma</z:e>, and four with other) received 216 treatment cycles </plain></SENT>
<SENT sid="5" pm="."><plain>Median age was 54 years (range, 21 to 72 years); 95% had PS of 0 to 1; <z:hpo ids='HP_0000001'>all</z:hpo> but six had failed fluorouracil (5-FU) chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>The maximum-tolerated dose was <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 110 mg/m(2) plus irinotecan 200 mg/m(2) in one study and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 110 mg/m(2) plus irinotecan 250 mg/m(2) in the other study </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3 to 4 <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> were dose-limiting toxicities; other toxicities included <z:hpo ids='HP_0002013'>emesis</z:hpo> and dose-cumulative <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Recommended dose for phase II studies is <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 85 mg/m(2) and irinotecan 200 mg/m(2) </plain></SENT>
<SENT sid="9" pm="."><plain>At this dose (12 patients, 65 cycles), grade 3 and 4 toxicities per patient included the following: <z:hpo ids='HP_0002013'>emesis</z:hpo> in 42% of patients, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 33% (febrile episodes in 17%), <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in 25%, delayed <z:hpo ids='HP_0002014'>diarrhea</z:hpo> in 17%, and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in 8% </plain></SENT>
<SENT sid="10" pm="."><plain>Two patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> experienced severe irinotecan toxicity </plain></SENT>
<SENT sid="11" pm="."><plain>No plasmatic pharmacokinetic interactions were detected </plain></SENT>
<SENT sid="12" pm="."><plain>Seven partial responses were observed in 24 CRC patients </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: This combination is feasible, with activity in 5-FU-resistant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="14" pm="."><plain>Phase I studies that explore the every-2-weeks schedule, in addition to phase II studies of this schedule (as well as in combination with 5-FU) as second-line therapy of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, are ongoing </plain></SENT>
</text></document>